In a report released yesterday, Thomas Stephan from Stifel Nicolaus maintained a Buy rating on Alcon (ALC – Research Report), with a price target of $100.00.
Thomas Stephan has given his Buy rating due to a combination of factors surrounding Alcon’s recent product developments and market potential. A key contributor to this positive outlook is the strong enthusiasm among US ophthalmologists for Alcon’s newly launched Voyager DSLT device, which promises significant efficiency improvements over existing SLT systems. Despite some reservations about adoption due to satisfaction with current devices and concerns over Voyager’s click fee, the projected revenue from Voyager is expected to contribute meaningfully to Alcon’s sales growth in 2025.
Moreover, the long-term prospects for Alcon appear promising due to the anticipated product cycle, particularly with the upcoming UNITY VCS. Thomas Stephan acknowledges that while there may be short-term challenges, such as the competitive landscape and initial guidance being slightly below market expectations, the overall trajectory for Alcon remains upward. The continued success and adoption of Voyager, alongside other innovations, are poised to strengthen Alcon’s position in the interventional glaucoma market.
In another report released on February 12, Wells Fargo also maintained a Buy rating on the stock with a $105.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com